Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HilleVax Inc
HLVX | US
1.83
USD-0.05
-2.66%
HLVX | US
About HilleVax Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.83
Open
1.88
High
1.88
Low
1.83
HilleVax Inc. a clinical-stage biopharmaceutical company focuses on developing and commercializing novel vaccines. The company develops HIL-214 a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo Inc. and changed its name to HilleVax Inc. in February 2021. HilleVax Inc. was founded in 2019 and is headquartered in Boston Massachusetts.
View LessHLVX | US
Risk
30.2
Sharpe
-0.85
Luna's Score
48/100
Recommendation
Hold
Luna says (HLVX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
36.1%1 month
30.2%3 months
47.8%6 months
138.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.46
Debt to equity
0.25
Debt to assets
0.18
Ent. to EBITDA
-4.07
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-141.70M
MarketCap
91.11M
MarketCap(USD)
91.11M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-73.77
Short ratio
6.84
Short perc.
22.69
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.19
Range1M
0.19
Range3M
0.49
Volumes: Market Activity
Rel. volume
0.40
Price X volume
123.33K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.07 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.46 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 47.81 | 72.80 | Lower Risk |
| Debt to Equity | 0.25 | -1.23 | Expensive |
| Debt to Assets | 0.18 | 0.25 | Cheaper |
| Market Cap | 91.11M | 3.66B | Emerging |
